Lipocine Inc. (LPCN) Soars 6.76%

Lipocine Inc. (LPCN) Soars 6.76%

Lipocine Inc. is a Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders.

Lipocine Inc. (LPCN) had a good day on the market for Monday November 23 as shares jumped 6.76% to close at $1.58. About 1.83 million shares traded hands on 3,783 trades for the day, compared with an average daily volume of n/a shares out of a total float of 65.69 million. After opening the trading day at $1.58, shares of Lipocine Inc. stayed within a range of $1.60 to $1.52.

With today’s gains, Lipocine Inc. now has a market cap of $103.78 million. Shares of Lipocine Inc. have been trading within a range of $2.40 and $0.31 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company’s product TLANDO, is an oral testosterone replacement therapy (“TRT”). It also has other products in the pipeline such as LPCN 1144, LPCN 1148 and LPCN 1107.

Lipocine Inc. is based out of Salt Lake City, UT and has some 12 employees. Its CEO is Mahesh V. Patel.

Share:
Scroll Up
error: Content is protected !!